nodes	percent_of_prediction	percent_of_DWPC	metapath
Sildenafil—ABCC10—Vincristine—peripheral nervous system neoplasm	0.0942	0.133	CbGbCtD
Sildenafil—ABCC5—Cisplatin—peripheral nervous system neoplasm	0.0879	0.124	CbGbCtD
Sildenafil—ABCC10—Etoposide—peripheral nervous system neoplasm	0.0864	0.122	CbGbCtD
Sildenafil—ABCC10—Doxorubicin—peripheral nervous system neoplasm	0.0589	0.0833	CbGbCtD
Sildenafil—CYP1A1—Tretinoin—peripheral nervous system neoplasm	0.0489	0.0692	CbGbCtD
Sildenafil—CYP1A1—Dacarbazine—peripheral nervous system neoplasm	0.0421	0.0595	CbGbCtD
Sildenafil—CYP3A7—Tretinoin—peripheral nervous system neoplasm	0.0392	0.0554	CbGbCtD
Sildenafil—CYP3A7-CYP3A51P—Tretinoin—peripheral nervous system neoplasm	0.0392	0.0554	CbGbCtD
Sildenafil—CYP2E1—Dacarbazine—peripheral nervous system neoplasm	0.0325	0.046	CbGbCtD
Sildenafil—CYP3A5—Tretinoin—peripheral nervous system neoplasm	0.0294	0.0416	CbGbCtD
Sildenafil—CYP2C9—Tretinoin—peripheral nervous system neoplasm	0.0197	0.0279	CbGbCtD
Sildenafil—CYP3A7—Vincristine—peripheral nervous system neoplasm	0.018	0.0254	CbGbCtD
Sildenafil—CYP3A7-CYP3A51P—Vincristine—peripheral nervous system neoplasm	0.018	0.0254	CbGbCtD
Sildenafil—CYP2E1—Etoposide—peripheral nervous system neoplasm	0.0159	0.0225	CbGbCtD
Sildenafil—CYP3A5—Vincristine—peripheral nervous system neoplasm	0.0135	0.0191	CbGbCtD
Sildenafil—CYP3A5—Etoposide—peripheral nervous system neoplasm	0.0124	0.0175	CbGbCtD
Sildenafil—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0123	0.0174	CbGbCtD
Sildenafil—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0115	0.0162	CbGbCtD
Sildenafil—CYP2C9—Cisplatin—peripheral nervous system neoplasm	0.00844	0.0119	CbGbCtD
Sildenafil—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.00526	0.00744	CbGbCtD
Sildenafil—CYP2D6—Doxorubicin—peripheral nervous system neoplasm	0.00517	0.00731	CbGbCtD
Sildenafil—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00482	0.00682	CbGbCtD
Sildenafil—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00329	0.00465	CbGbCtD
Sildenafil—ABCC4—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	0.000132	0.00444	CbGpPWpGaD
Sildenafil—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.00013	0.00437	CbGpPWpGaD
Sildenafil—PDE6G—Disease—GNS—peripheral nervous system neoplasm	0.000129	0.00435	CbGpPWpGaD
Sildenafil—ADORA2A—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000127	0.00429	CbGpPWpGaD
Sildenafil—PDE5A—Hemostasis—IFNB1—peripheral nervous system neoplasm	0.000126	0.00425	CbGpPWpGaD
Sildenafil—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000124	0.00417	CbGpPWpGaD
Sildenafil—ADORA2A—NGF signalling via TRKA from the plasma membrane—NTRK2—peripheral nervous system neoplasm	0.000123	0.00414	CbGpPWpGaD
Sildenafil—ADORA2A—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000122	0.00411	CbGpPWpGaD
Sildenafil—ABCC5—Carbohydrate metabolism—SLC2A1—peripheral nervous system neoplasm	0.00012	0.00405	CbGpPWpGaD
Sildenafil—ABCC5—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000119	0.00403	CbGpPWpGaD
Sildenafil—PDE5A—Hemostasis—KNG1—peripheral nervous system neoplasm	0.000117	0.00394	CbGpPWpGaD
Sildenafil—ABCC10—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	0.000116	0.00391	CbGpPWpGaD
Sildenafil—ABCC5—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000115	0.00388	CbGpPWpGaD
Sildenafil—ADORA2A—Circadian rythm related genes—TH—peripheral nervous system neoplasm	0.000115	0.00387	CbGpPWpGaD
Sildenafil—ABCC4—Fluoropyrimidine Activity—TP53—peripheral nervous system neoplasm	0.000111	0.00375	CbGpPWpGaD
Sildenafil—PDE5A—Hemostasis—GNAS—peripheral nervous system neoplasm	0.000102	0.00344	CbGpPWpGaD
Sildenafil—ADORA2A—Circadian rythm related genes—NTRK1—peripheral nervous system neoplasm	0.000102	0.00344	CbGpPWpGaD
Sildenafil—ABCC4—NRF2 pathway—HGF—peripheral nervous system neoplasm	0.000101	0.0034	CbGpPWpGaD
Sildenafil—ADORA2A—NGF signalling via TRKA from the plasma membrane—NTRK1—peripheral nervous system neoplasm	0.0001	0.00337	CbGpPWpGaD
Sildenafil—PDE5A—Hemostasis—HGF—peripheral nervous system neoplasm	9.72e-05	0.00328	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by NGF—NTRK2—peripheral nervous system neoplasm	9.43e-05	0.00318	CbGpPWpGaD
Sildenafil—ABCC10—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	9.32e-05	0.00314	CbGpPWpGaD
Sildenafil—ABCC10—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	9.14e-05	0.00308	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—NTS—peripheral nervous system neoplasm	9.03e-05	0.00305	CbGpPWpGaD
Sildenafil—PDE6G—Disease—PPP3R1—peripheral nervous system neoplasm	9.02e-05	0.00304	CbGpPWpGaD
Sildenafil—ABCC4—Platelet activation, signaling and aggregation—KNG1—peripheral nervous system neoplasm	8.69e-05	0.00293	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—CD55—peripheral nervous system neoplasm	8.66e-05	0.00292	CbGpPWpGaD
Sildenafil—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	8.55e-05	0.00288	CbGpPWpGaD
Sildenafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	8.15e-05	0.00275	CbGpPWpGaD
Sildenafil—Paraesthesia—Etoposide—peripheral nervous system neoplasm	8.11e-05	0.000308	CcSEcCtD
Sildenafil—Weight increased—Epirubicin—peripheral nervous system neoplasm	8.11e-05	0.000308	CcSEcCtD
Sildenafil—ABCC5—Metabolism—HSD17B12—peripheral nervous system neoplasm	8.07e-05	0.00272	CbGpPWpGaD
Sildenafil—Dyspnoea—Etoposide—peripheral nervous system neoplasm	8.06e-05	0.000306	CcSEcCtD
Sildenafil—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	8.03e-05	0.000305	CcSEcCtD
Sildenafil—Somnolence—Etoposide—peripheral nervous system neoplasm	8.03e-05	0.000305	CcSEcCtD
Sildenafil—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	8.03e-05	0.000305	CcSEcCtD
Sildenafil—Asthenia—Vincristine—peripheral nervous system neoplasm	8e-05	0.000304	CcSEcCtD
Sildenafil—Pneumonia—Epirubicin—peripheral nervous system neoplasm	7.99e-05	0.000303	CcSEcCtD
Sildenafil—ABCC4—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	7.97e-05	0.00269	CbGpPWpGaD
Sildenafil—Infestation—Epirubicin—peripheral nervous system neoplasm	7.94e-05	0.000301	CcSEcCtD
Sildenafil—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	7.94e-05	0.000301	CcSEcCtD
Sildenafil—Vomiting—Dactinomycin—peripheral nervous system neoplasm	7.94e-05	0.000301	CcSEcCtD
Sildenafil—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	7.93e-05	0.000301	CcSEcCtD
Sildenafil—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	7.92e-05	0.000301	CcSEcCtD
Sildenafil—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	7.87e-05	0.000299	CcSEcCtD
Sildenafil—Rash—Dactinomycin—peripheral nervous system neoplasm	7.87e-05	0.000299	CcSEcCtD
Sildenafil—Decreased appetite—Etoposide—peripheral nervous system neoplasm	7.85e-05	0.000298	CcSEcCtD
Sildenafil—PDE6G—Disease—ENO2—peripheral nervous system neoplasm	7.82e-05	0.00264	CbGpPWpGaD
Sildenafil—Renal failure—Epirubicin—peripheral nervous system neoplasm	7.81e-05	0.000296	CcSEcCtD
Sildenafil—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	7.8e-05	0.000296	CcSEcCtD
Sildenafil—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	7.8e-05	0.000296	CcSEcCtD
Sildenafil—Fatigue—Etoposide—peripheral nervous system neoplasm	7.79e-05	0.000296	CcSEcCtD
Sildenafil—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	7.78e-05	0.000295	CcSEcCtD
Sildenafil—Stomatitis—Epirubicin—peripheral nervous system neoplasm	7.74e-05	0.000294	CcSEcCtD
Sildenafil—Constipation—Etoposide—peripheral nervous system neoplasm	7.73e-05	0.000293	CcSEcCtD
Sildenafil—Pain—Etoposide—peripheral nervous system neoplasm	7.73e-05	0.000293	CcSEcCtD
Sildenafil—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	7.72e-05	0.000293	CcSEcCtD
Sildenafil—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	7.72e-05	0.000293	CcSEcCtD
Sildenafil—ADORA2A—Signaling by NGF—NTRK1—peripheral nervous system neoplasm	7.69e-05	0.00259	CbGpPWpGaD
Sildenafil—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	7.66e-05	0.000291	CcSEcCtD
Sildenafil—Dizziness—Alitretinoin—peripheral nervous system neoplasm	7.65e-05	0.000291	CcSEcCtD
Sildenafil—Diarrhoea—Vincristine—peripheral nervous system neoplasm	7.63e-05	0.00029	CcSEcCtD
Sildenafil—Sweating—Epirubicin—peripheral nervous system neoplasm	7.61e-05	0.000289	CcSEcCtD
Sildenafil—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	7.61e-05	0.000289	CcSEcCtD
Sildenafil—Haematuria—Epirubicin—peripheral nervous system neoplasm	7.57e-05	0.000287	CcSEcCtD
Sildenafil—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	7.52e-05	0.000286	CcSEcCtD
Sildenafil—ADORA2A—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	7.51e-05	0.00253	CbGpPWpGaD
Sildenafil—Weight increased—Doxorubicin—peripheral nervous system neoplasm	7.5e-05	0.000285	CcSEcCtD
Sildenafil—Epistaxis—Epirubicin—peripheral nervous system neoplasm	7.49e-05	0.000284	CcSEcCtD
Sildenafil—Sinusitis—Epirubicin—peripheral nervous system neoplasm	7.45e-05	0.000283	CcSEcCtD
Sildenafil—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	7.45e-05	0.000283	CcSEcCtD
Sildenafil—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	7.43e-05	0.000282	CcSEcCtD
Sildenafil—Nausea—Dactinomycin—peripheral nervous system neoplasm	7.42e-05	0.000281	CcSEcCtD
Sildenafil—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	7.39e-05	0.000281	CcSEcCtD
Sildenafil—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	7.39e-05	0.00028	CcSEcCtD
Sildenafil—Dizziness—Vincristine—peripheral nervous system neoplasm	7.38e-05	0.00028	CcSEcCtD
Sildenafil—Vomiting—Alitretinoin—peripheral nervous system neoplasm	7.36e-05	0.000279	CcSEcCtD
Sildenafil—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	7.35e-05	0.000279	CcSEcCtD
Sildenafil—Infestation—Doxorubicin—peripheral nervous system neoplasm	7.35e-05	0.000279	CcSEcCtD
Sildenafil—Rash—Alitretinoin—peripheral nervous system neoplasm	7.3e-05	0.000277	CcSEcCtD
Sildenafil—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	7.29e-05	0.000277	CcSEcCtD
Sildenafil—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	7.29e-05	0.000277	CcSEcCtD
Sildenafil—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	7.27e-05	0.000276	CcSEcCtD
Sildenafil—Headache—Alitretinoin—peripheral nervous system neoplasm	7.25e-05	0.000275	CcSEcCtD
Sildenafil—ABCC4—Platelet activation, signaling and aggregation—HGF—peripheral nervous system neoplasm	7.24e-05	0.00244	CbGpPWpGaD
Sildenafil—Renal failure—Doxorubicin—peripheral nervous system neoplasm	7.22e-05	0.000274	CcSEcCtD
Sildenafil—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	7.2e-05	0.000273	CcSEcCtD
Sildenafil—ADORA2A—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	7.19e-05	0.00242	CbGpPWpGaD
Sildenafil—Urticaria—Etoposide—peripheral nervous system neoplasm	7.18e-05	0.000272	CcSEcCtD
Sildenafil—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	7.17e-05	0.000272	CcSEcCtD
Sildenafil—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	7.16e-05	0.000272	CcSEcCtD
Sildenafil—Rhinitis—Epirubicin—peripheral nervous system neoplasm	7.15e-05	0.000271	CcSEcCtD
Sildenafil—Abdominal pain—Etoposide—peripheral nervous system neoplasm	7.14e-05	0.000271	CcSEcCtD
Sildenafil—Body temperature increased—Etoposide—peripheral nervous system neoplasm	7.14e-05	0.000271	CcSEcCtD
Sildenafil—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	7.14e-05	0.000271	CcSEcCtD
Sildenafil—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	7.14e-05	0.000271	CcSEcCtD
Sildenafil—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	7.13e-05	0.000271	CcSEcCtD
Sildenafil—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	7.09e-05	0.000269	CcSEcCtD
Sildenafil—Vomiting—Vincristine—peripheral nervous system neoplasm	7.09e-05	0.000269	CcSEcCtD
Sildenafil—PDE5A—Hemostasis—PTPN11—peripheral nervous system neoplasm	7.09e-05	0.00239	CbGpPWpGaD
Sildenafil—Asthenia—Cisplatin—peripheral nervous system neoplasm	7.08e-05	0.000269	CcSEcCtD
Sildenafil—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	7.08e-05	0.000269	CcSEcCtD
Sildenafil—Sweating—Doxorubicin—peripheral nervous system neoplasm	7.04e-05	0.000267	CcSEcCtD
Sildenafil—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	7.04e-05	0.000267	CcSEcCtD
Sildenafil—Rash—Vincristine—peripheral nervous system neoplasm	7.03e-05	0.000267	CcSEcCtD
Sildenafil—Dermatitis—Vincristine—peripheral nervous system neoplasm	7.03e-05	0.000267	CcSEcCtD
Sildenafil—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	7.02e-05	0.000267	CcSEcCtD
Sildenafil—Haematuria—Doxorubicin—peripheral nervous system neoplasm	7.01e-05	0.000266	CcSEcCtD
Sildenafil—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	7.01e-05	0.000266	CcSEcCtD
Sildenafil—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	6.99e-05	0.000265	CcSEcCtD
Sildenafil—Headache—Vincristine—peripheral nervous system neoplasm	6.99e-05	0.000265	CcSEcCtD
Sildenafil—ABCC5—Disease—GNS—peripheral nervous system neoplasm	6.97e-05	0.00235	CbGpPWpGaD
Sildenafil—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	6.93e-05	0.000263	CcSEcCtD
Sildenafil—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	6.89e-05	0.000262	CcSEcCtD
Sildenafil—Nausea—Alitretinoin—peripheral nervous system neoplasm	6.88e-05	0.000261	CcSEcCtD
Sildenafil—Visual impairment—Epirubicin—peripheral nervous system neoplasm	6.87e-05	0.000261	CcSEcCtD
Sildenafil—PDE6G—Signaling Pathways—VIP—peripheral nervous system neoplasm	6.85e-05	0.00231	CbGpPWpGaD
Sildenafil—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	6.75e-05	0.000256	CcSEcCtD
Sildenafil—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	6.74e-05	0.000256	CcSEcCtD
Sildenafil—Eye disorder—Epirubicin—peripheral nervous system neoplasm	6.66e-05	0.000253	CcSEcCtD
Sildenafil—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	6.66e-05	0.000253	CcSEcCtD
Sildenafil—Tinnitus—Epirubicin—peripheral nervous system neoplasm	6.65e-05	0.000252	CcSEcCtD
Sildenafil—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	6.63e-05	0.000252	CcSEcCtD
Sildenafil—Nausea—Vincristine—peripheral nervous system neoplasm	6.63e-05	0.000251	CcSEcCtD
Sildenafil—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	6.62e-05	0.000251	CcSEcCtD
Sildenafil—Flushing—Epirubicin—peripheral nervous system neoplasm	6.62e-05	0.000251	CcSEcCtD
Sildenafil—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	6.61e-05	0.000251	CcSEcCtD
Sildenafil—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	6.6e-05	0.00025	CcSEcCtD
Sildenafil—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	6.56e-05	0.000249	CcSEcCtD
Sildenafil—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	6.55e-05	0.000248	CcSEcCtD
Sildenafil—ADORA2A—Signaling by GPCR—NTS—peripheral nervous system neoplasm	6.53e-05	0.0022	CbGpPWpGaD
Sildenafil—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	6.51e-05	0.000247	CcSEcCtD
Sildenafil—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	6.5e-05	0.000247	CcSEcCtD
Sildenafil—Asthenia—Etoposide—peripheral nervous system neoplasm	6.48e-05	0.000246	CcSEcCtD
Sildenafil—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	6.48e-05	0.000246	CcSEcCtD
Sildenafil—Angiopathy—Epirubicin—peripheral nervous system neoplasm	6.47e-05	0.000246	CcSEcCtD
Sildenafil—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	6.47e-05	0.000245	CcSEcCtD
Sildenafil—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	6.44e-05	0.000244	CcSEcCtD
Sildenafil—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	6.43e-05	0.000244	CcSEcCtD
Sildenafil—Chills—Epirubicin—peripheral nervous system neoplasm	6.4e-05	0.000243	CcSEcCtD
Sildenafil—Pruritus—Etoposide—peripheral nervous system neoplasm	6.39e-05	0.000243	CcSEcCtD
Sildenafil—ADORA2A—NGF signalling via TRKA from the plasma membrane—PTPN11—peripheral nervous system neoplasm	6.37e-05	0.00215	CbGpPWpGaD
Sildenafil—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	6.37e-05	0.000242	CcSEcCtD
Sildenafil—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	6.36e-05	0.000241	CcSEcCtD
Sildenafil—PDE6G—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	6.32e-05	0.00213	CbGpPWpGaD
Sildenafil—PDE6G—Disease—SLC2A1—peripheral nervous system neoplasm	6.3e-05	0.00213	CbGpPWpGaD
Sildenafil—Alopecia—Epirubicin—peripheral nervous system neoplasm	6.3e-05	0.000239	CcSEcCtD
Sildenafil—Vomiting—Cisplatin—peripheral nervous system neoplasm	6.27e-05	0.000238	CcSEcCtD
Sildenafil—ADORA2A—Signaling by GPCR—CD55—peripheral nervous system neoplasm	6.26e-05	0.00211	CbGpPWpGaD
Sildenafil—Mental disorder—Epirubicin—peripheral nervous system neoplasm	6.25e-05	0.000237	CcSEcCtD
Sildenafil—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	6.24e-05	0.000237	CcSEcCtD
Sildenafil—CYP1A1—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	6.23e-05	0.0021	CbGpPWpGaD
Sildenafil—Rash—Cisplatin—peripheral nervous system neoplasm	6.22e-05	0.000236	CcSEcCtD
Sildenafil—Dermatitis—Cisplatin—peripheral nervous system neoplasm	6.21e-05	0.000236	CcSEcCtD
Sildenafil—Malnutrition—Epirubicin—peripheral nervous system neoplasm	6.21e-05	0.000236	CcSEcCtD
Sildenafil—Erythema—Epirubicin—peripheral nervous system neoplasm	6.21e-05	0.000236	CcSEcCtD
Sildenafil—Diarrhoea—Etoposide—peripheral nervous system neoplasm	6.18e-05	0.000235	CcSEcCtD
Sildenafil—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	6.16e-05	0.000234	CcSEcCtD
Sildenafil—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	6.15e-05	0.000233	CcSEcCtD
Sildenafil—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	6.12e-05	0.000232	CcSEcCtD
Sildenafil—Flushing—Doxorubicin—peripheral nervous system neoplasm	6.12e-05	0.000232	CcSEcCtD
Sildenafil—Flatulence—Epirubicin—peripheral nervous system neoplasm	6.12e-05	0.000232	CcSEcCtD
Sildenafil—Tension—Epirubicin—peripheral nervous system neoplasm	6.09e-05	0.000231	CcSEcCtD
Sildenafil—ABCC5—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	6.08e-05	0.00205	CbGpPWpGaD
Sildenafil—Nervousness—Epirubicin—peripheral nervous system neoplasm	6.03e-05	0.000229	CcSEcCtD
Sildenafil—CYP3A7—Metabolism—PPIP5K2—peripheral nervous system neoplasm	6.02e-05	0.00203	CbGpPWpGaD
Sildenafil—Back pain—Epirubicin—peripheral nervous system neoplasm	6e-05	0.000228	CcSEcCtD
Sildenafil—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	5.98e-05	0.000227	CcSEcCtD
Sildenafil—Dizziness—Etoposide—peripheral nervous system neoplasm	5.98e-05	0.000227	CcSEcCtD
Sildenafil—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	5.96e-05	0.000226	CcSEcCtD
Sildenafil—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	5.95e-05	0.000226	CcSEcCtD
Sildenafil—PDE6G—Signaling by Wnt—MYC—peripheral nervous system neoplasm	5.92e-05	0.002	CbGpPWpGaD
Sildenafil—Chills—Doxorubicin—peripheral nervous system neoplasm	5.92e-05	0.000225	CcSEcCtD
Sildenafil—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	5.89e-05	0.000224	CcSEcCtD
Sildenafil—Nausea—Cisplatin—peripheral nervous system neoplasm	5.86e-05	0.000222	CcSEcCtD
Sildenafil—Vision blurred—Epirubicin—peripheral nervous system neoplasm	5.85e-05	0.000222	CcSEcCtD
Sildenafil—ABCC5—Metabolism—GNS—peripheral nervous system neoplasm	5.83e-05	0.00197	CbGpPWpGaD
Sildenafil—Alopecia—Doxorubicin—peripheral nervous system neoplasm	5.83e-05	0.000221	CcSEcCtD
Sildenafil—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	5.78e-05	0.000219	CcSEcCtD
Sildenafil—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	5.76e-05	0.000219	CcSEcCtD
Sildenafil—Vomiting—Etoposide—peripheral nervous system neoplasm	5.75e-05	0.000218	CcSEcCtD
Sildenafil—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	5.74e-05	0.000218	CcSEcCtD
Sildenafil—Erythema—Doxorubicin—peripheral nervous system neoplasm	5.74e-05	0.000218	CcSEcCtD
Sildenafil—Anaemia—Epirubicin—peripheral nervous system neoplasm	5.74e-05	0.000218	CcSEcCtD
Sildenafil—ADORA2A—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	5.72e-05	0.00193	CbGpPWpGaD
Sildenafil—Agitation—Epirubicin—peripheral nervous system neoplasm	5.7e-05	0.000216	CcSEcCtD
Sildenafil—Rash—Etoposide—peripheral nervous system neoplasm	5.7e-05	0.000216	CcSEcCtD
Sildenafil—Dermatitis—Etoposide—peripheral nervous system neoplasm	5.69e-05	0.000216	CcSEcCtD
Sildenafil—Headache—Etoposide—peripheral nervous system neoplasm	5.66e-05	0.000215	CcSEcCtD
Sildenafil—Flatulence—Doxorubicin—peripheral nervous system neoplasm	5.66e-05	0.000215	CcSEcCtD
Sildenafil—Tension—Doxorubicin—peripheral nervous system neoplasm	5.64e-05	0.000214	CcSEcCtD
Sildenafil—Malaise—Epirubicin—peripheral nervous system neoplasm	5.6e-05	0.000212	CcSEcCtD
Sildenafil—ABCC5—Metabolism—NME1—peripheral nervous system neoplasm	5.59e-05	0.00189	CbGpPWpGaD
Sildenafil—Nervousness—Doxorubicin—peripheral nervous system neoplasm	5.58e-05	0.000212	CcSEcCtD
Sildenafil—Vertigo—Epirubicin—peripheral nervous system neoplasm	5.58e-05	0.000212	CcSEcCtD
Sildenafil—Syncope—Epirubicin—peripheral nervous system neoplasm	5.57e-05	0.000211	CcSEcCtD
Sildenafil—Leukopenia—Epirubicin—peripheral nervous system neoplasm	5.56e-05	0.000211	CcSEcCtD
Sildenafil—Back pain—Doxorubicin—peripheral nervous system neoplasm	5.55e-05	0.000211	CcSEcCtD
Sildenafil—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	5.54e-05	0.00187	CbGpPWpGaD
Sildenafil—Palpitations—Epirubicin—peripheral nervous system neoplasm	5.48e-05	0.000208	CcSEcCtD
Sildenafil—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	5.45e-05	0.000207	CcSEcCtD
Sildenafil—ADORA2A—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	5.45e-05	0.00184	CbGpPWpGaD
Sildenafil—Cough—Epirubicin—peripheral nervous system neoplasm	5.42e-05	0.000206	CcSEcCtD
Sildenafil—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	5.41e-05	0.000205	CcSEcCtD
Sildenafil—ABCC5—Metabolism—COX2—peripheral nervous system neoplasm	5.38e-05	0.00182	CbGpPWpGaD
Sildenafil—Convulsion—Epirubicin—peripheral nervous system neoplasm	5.38e-05	0.000204	CcSEcCtD
Sildenafil—Nausea—Etoposide—peripheral nervous system neoplasm	5.37e-05	0.000204	CcSEcCtD
Sildenafil—Hypertension—Epirubicin—peripheral nervous system neoplasm	5.36e-05	0.000203	CcSEcCtD
Sildenafil—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	5.33e-05	0.000202	CcSEcCtD
Sildenafil—Anaemia—Doxorubicin—peripheral nervous system neoplasm	5.31e-05	0.000201	CcSEcCtD
Sildenafil—Chest pain—Epirubicin—peripheral nervous system neoplasm	5.28e-05	0.000201	CcSEcCtD
Sildenafil—Arthralgia—Epirubicin—peripheral nervous system neoplasm	5.28e-05	0.000201	CcSEcCtD
Sildenafil—Myalgia—Epirubicin—peripheral nervous system neoplasm	5.28e-05	0.000201	CcSEcCtD
Sildenafil—Agitation—Doxorubicin—peripheral nervous system neoplasm	5.28e-05	0.0002	CcSEcCtD
Sildenafil—Anxiety—Epirubicin—peripheral nervous system neoplasm	5.27e-05	0.0002	CcSEcCtD
Sildenafil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	5.25e-05	0.000199	CcSEcCtD
Sildenafil—Discomfort—Epirubicin—peripheral nervous system neoplasm	5.22e-05	0.000198	CcSEcCtD
Sildenafil—Malaise—Doxorubicin—peripheral nervous system neoplasm	5.18e-05	0.000197	CcSEcCtD
Sildenafil—Dry mouth—Epirubicin—peripheral nervous system neoplasm	5.17e-05	0.000196	CcSEcCtD
Sildenafil—Vertigo—Doxorubicin—peripheral nervous system neoplasm	5.16e-05	0.000196	CcSEcCtD
Sildenafil—CYP1A1—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	5.16e-05	0.00174	CbGpPWpGaD
Sildenafil—Syncope—Doxorubicin—peripheral nervous system neoplasm	5.15e-05	0.000195	CcSEcCtD
Sildenafil—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	5.14e-05	0.000195	CcSEcCtD
Sildenafil—CYP2C19—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	5.1e-05	0.00172	CbGpPWpGaD
Sildenafil—Palpitations—Doxorubicin—peripheral nervous system neoplasm	5.07e-05	0.000193	CcSEcCtD
Sildenafil—Oedema—Epirubicin—peripheral nervous system neoplasm	5.07e-05	0.000192	CcSEcCtD
Sildenafil—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	5.05e-05	0.000192	CcSEcCtD
Sildenafil—ADORA2A—NGF signalling via TRKA from the plasma membrane—ERBB2—peripheral nervous system neoplasm	5.04e-05	0.0017	CbGpPWpGaD
Sildenafil—Infection—Epirubicin—peripheral nervous system neoplasm	5.03e-05	0.000191	CcSEcCtD
Sildenafil—Cough—Doxorubicin—peripheral nervous system neoplasm	5.01e-05	0.00019	CcSEcCtD
Sildenafil—ADORA2A—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	5e-05	0.00169	CbGpPWpGaD
Sildenafil—Shock—Epirubicin—peripheral nervous system neoplasm	4.98e-05	0.000189	CcSEcCtD
Sildenafil—Convulsion—Doxorubicin—peripheral nervous system neoplasm	4.98e-05	0.000189	CcSEcCtD
Sildenafil—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	4.97e-05	0.000189	CcSEcCtD
Sildenafil—Hypertension—Doxorubicin—peripheral nervous system neoplasm	4.96e-05	0.000188	CcSEcCtD
Sildenafil—ADORA2A—Signaling by GPCR—VIP—peripheral nervous system neoplasm	4.95e-05	0.00167	CbGpPWpGaD
Sildenafil—Tachycardia—Epirubicin—peripheral nervous system neoplasm	4.94e-05	0.000188	CcSEcCtD
Sildenafil—Skin disorder—Epirubicin—peripheral nervous system neoplasm	4.92e-05	0.000187	CcSEcCtD
Sildenafil—ADORA2A—Signaling by NGF—PTPN11—peripheral nervous system neoplasm	4.9e-05	0.00165	CbGpPWpGaD
Sildenafil—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	4.9e-05	0.000186	CcSEcCtD
Sildenafil—ABCC5—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	4.89e-05	0.00165	CbGpPWpGaD
Sildenafil—Chest pain—Doxorubicin—peripheral nervous system neoplasm	4.89e-05	0.000186	CcSEcCtD
Sildenafil—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	4.89e-05	0.000186	CcSEcCtD
Sildenafil—Myalgia—Doxorubicin—peripheral nervous system neoplasm	4.89e-05	0.000186	CcSEcCtD
Sildenafil—ABCC5—Disease—PPP3R1—peripheral nervous system neoplasm	4.87e-05	0.00164	CbGpPWpGaD
Sildenafil—Anxiety—Doxorubicin—peripheral nervous system neoplasm	4.87e-05	0.000185	CcSEcCtD
Sildenafil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	4.86e-05	0.000184	CcSEcCtD
Sildenafil—ABCC4—Hemostasis—IFNB1—peripheral nervous system neoplasm	4.84e-05	0.00163	CbGpPWpGaD
Sildenafil—Discomfort—Doxorubicin—peripheral nervous system neoplasm	4.83e-05	0.000183	CcSEcCtD
Sildenafil—Anorexia—Epirubicin—peripheral nervous system neoplasm	4.83e-05	0.000183	CcSEcCtD
Sildenafil—ABCC5—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	4.8e-05	0.00162	CbGpPWpGaD
Sildenafil—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	4.78e-05	0.000181	CcSEcCtD
Sildenafil—PDE6G—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	4.75e-05	0.0016	CbGpPWpGaD
Sildenafil—Hypotension—Epirubicin—peripheral nervous system neoplasm	4.73e-05	0.00018	CcSEcCtD
Sildenafil—Oedema—Doxorubicin—peripheral nervous system neoplasm	4.69e-05	0.000178	CcSEcCtD
Sildenafil—Infection—Doxorubicin—peripheral nervous system neoplasm	4.66e-05	0.000177	CcSEcCtD
Sildenafil—CYP2C9—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	4.65e-05	0.00157	CbGpPWpGaD
Sildenafil—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	4.61e-05	0.000175	CcSEcCtD
Sildenafil—Shock—Doxorubicin—peripheral nervous system neoplasm	4.61e-05	0.000175	CcSEcCtD
Sildenafil—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	4.6e-05	0.000174	CcSEcCtD
Sildenafil—Insomnia—Epirubicin—peripheral nervous system neoplasm	4.58e-05	0.000174	CcSEcCtD
Sildenafil—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	4.57e-05	0.000174	CcSEcCtD
Sildenafil—ADORA2A—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	4.57e-05	0.00154	CbGpPWpGaD
Sildenafil—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	4.55e-05	0.000173	CcSEcCtD
Sildenafil—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	4.55e-05	0.000173	CcSEcCtD
Sildenafil—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	4.53e-05	0.000172	CcSEcCtD
Sildenafil—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	4.52e-05	0.000171	CcSEcCtD
Sildenafil—Somnolence—Epirubicin—peripheral nervous system neoplasm	4.5e-05	0.000171	CcSEcCtD
Sildenafil—ABCC4—Hemostasis—KNG1—peripheral nervous system neoplasm	4.48e-05	0.00151	CbGpPWpGaD
Sildenafil—Anorexia—Doxorubicin—peripheral nervous system neoplasm	4.47e-05	0.00017	CcSEcCtD
Sildenafil—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	4.46e-05	0.000169	CcSEcCtD
Sildenafil—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	4.4e-05	0.000167	CcSEcCtD
Sildenafil—Hypotension—Doxorubicin—peripheral nervous system neoplasm	4.38e-05	0.000166	CcSEcCtD
Sildenafil—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	4.37e-05	0.000166	CcSEcCtD
Sildenafil—Fatigue—Epirubicin—peripheral nervous system neoplasm	4.37e-05	0.000166	CcSEcCtD
Sildenafil—CYP2E1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	4.36e-05	0.00147	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—PPIP5K2—peripheral nervous system neoplasm	4.35e-05	0.00147	CbGpPWpGaD
Sildenafil—Pain—Epirubicin—peripheral nervous system neoplasm	4.33e-05	0.000164	CcSEcCtD
Sildenafil—Constipation—Epirubicin—peripheral nervous system neoplasm	4.33e-05	0.000164	CcSEcCtD
Sildenafil—ABCC4—Ectoderm Differentiation—MYC—peripheral nervous system neoplasm	4.31e-05	0.00145	CbGpPWpGaD
Sildenafil—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	4.27e-05	0.000162	CcSEcCtD
Sildenafil—PDE5A—Hemostasis—NRAS—peripheral nervous system neoplasm	4.26e-05	0.00144	CbGpPWpGaD
Sildenafil—Insomnia—Doxorubicin—peripheral nervous system neoplasm	4.24e-05	0.000161	CcSEcCtD
Sildenafil—ABCC5—Disease—ENO2—peripheral nervous system neoplasm	4.22e-05	0.00142	CbGpPWpGaD
Sildenafil—ABCC4—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	4.22e-05	0.00142	CbGpPWpGaD
Sildenafil—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	4.21e-05	0.00016	CcSEcCtD
Sildenafil—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	4.18e-05	0.000159	CcSEcCtD
Sildenafil—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	4.17e-05	0.000158	CcSEcCtD
Sildenafil—Somnolence—Doxorubicin—peripheral nervous system neoplasm	4.17e-05	0.000158	CcSEcCtD
Sildenafil—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	4.14e-05	0.000157	CcSEcCtD
Sildenafil—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	4.13e-05	0.000157	CcSEcCtD
Sildenafil—CYP1A1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	4.11e-05	0.00139	CbGpPWpGaD
Sildenafil—PDE6G—Signaling by Wnt—AKT1—peripheral nervous system neoplasm	4.11e-05	0.00139	CbGpPWpGaD
Sildenafil—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	4.07e-05	0.000155	CcSEcCtD
Sildenafil—CYP3A7—Metabolism—HSD17B12—peripheral nervous system neoplasm	4.07e-05	0.00137	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—KNG1—peripheral nervous system neoplasm	4.06e-05	0.00137	CbGpPWpGaD
Sildenafil—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	4.05e-05	0.00137	CbGpPWpGaD
Sildenafil—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	4.05e-05	0.000154	CcSEcCtD
Sildenafil—Fatigue—Doxorubicin—peripheral nervous system neoplasm	4.04e-05	0.000153	CcSEcCtD
Sildenafil—Urticaria—Epirubicin—peripheral nervous system neoplasm	4.02e-05	0.000153	CcSEcCtD
Sildenafil—Pain—Doxorubicin—peripheral nervous system neoplasm	4.01e-05	0.000152	CcSEcCtD
Sildenafil—Constipation—Doxorubicin—peripheral nervous system neoplasm	4.01e-05	0.000152	CcSEcCtD
Sildenafil—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	4e-05	0.000152	CcSEcCtD
Sildenafil—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	4e-05	0.000152	CcSEcCtD
Sildenafil—ABCC4—Hemostasis—GNAS—peripheral nervous system neoplasm	3.92e-05	0.00132	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by NGF—ERBB2—peripheral nervous system neoplasm	3.87e-05	0.00131	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	3.87e-05	0.00131	CbGpPWpGaD
Sildenafil—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	3.86e-05	0.000147	CcSEcCtD
Sildenafil—ADORA2A—Signaling Pathways—NTS—peripheral nervous system neoplasm	3.86e-05	0.0013	CbGpPWpGaD
Sildenafil—ADORA2A—NGF signalling via TRKA from the plasma membrane—NRAS—peripheral nervous system neoplasm	3.83e-05	0.00129	CbGpPWpGaD
Sildenafil—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	3.83e-05	0.000145	CcSEcCtD
Sildenafil—ABCC4—Hemostasis—HGF—peripheral nervous system neoplasm	3.73e-05	0.00126	CbGpPWpGaD
Sildenafil—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	3.73e-05	0.000142	CcSEcCtD
Sildenafil—Urticaria—Doxorubicin—peripheral nervous system neoplasm	3.72e-05	0.000141	CcSEcCtD
Sildenafil—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	3.7e-05	0.000141	CcSEcCtD
Sildenafil—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	3.7e-05	0.000141	CcSEcCtD
Sildenafil—ADORA2A—Signaling Pathways—CD55—peripheral nervous system neoplasm	3.7e-05	0.00125	CbGpPWpGaD
Sildenafil—Asthenia—Epirubicin—peripheral nervous system neoplasm	3.63e-05	0.000138	CcSEcCtD
Sildenafil—Pruritus—Epirubicin—peripheral nervous system neoplasm	3.58e-05	0.000136	CcSEcCtD
Sildenafil—PDE6G—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.55e-05	0.0012	CbGpPWpGaD
Sildenafil—ABCC5—Metabolism—ENO2—peripheral nervous system neoplasm	3.53e-05	0.00119	CbGpPWpGaD
Sildenafil—PDE6G—Disease—PTPN11—peripheral nervous system neoplasm	3.52e-05	0.00119	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by NGF—CASP3—peripheral nervous system neoplasm	3.52e-05	0.00119	CbGpPWpGaD
Sildenafil—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	3.47e-05	0.000132	CcSEcCtD
Sildenafil—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	3.45e-05	0.000131	CcSEcCtD
Sildenafil—ABCC5—Disease—SLC2A1—peripheral nervous system neoplasm	3.4e-05	0.00115	CbGpPWpGaD
Sildenafil—ABCC4—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	3.39e-05	0.00114	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—PPIP5K2—peripheral nervous system neoplasm	3.36e-05	0.00113	CbGpPWpGaD
Sildenafil—Asthenia—Doxorubicin—peripheral nervous system neoplasm	3.36e-05	0.000128	CcSEcCtD
Sildenafil—Dizziness—Epirubicin—peripheral nervous system neoplasm	3.35e-05	0.000127	CcSEcCtD
Sildenafil—ABCC4—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	3.33e-05	0.00112	CbGpPWpGaD
Sildenafil—Pruritus—Doxorubicin—peripheral nervous system neoplasm	3.32e-05	0.000126	CcSEcCtD
Sildenafil—PDE5A—Hemostasis—TP53—peripheral nervous system neoplasm	3.26e-05	0.0011	CbGpPWpGaD
Sildenafil—ADORA2A—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	3.23e-05	0.00109	CbGpPWpGaD
Sildenafil—Vomiting—Epirubicin—peripheral nervous system neoplasm	3.22e-05	0.000122	CcSEcCtD
Sildenafil—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	3.21e-05	0.000122	CcSEcCtD
Sildenafil—Rash—Epirubicin—peripheral nervous system neoplasm	3.19e-05	0.000121	CcSEcCtD
Sildenafil—Dermatitis—Epirubicin—peripheral nervous system neoplasm	3.19e-05	0.000121	CcSEcCtD
Sildenafil—Headache—Epirubicin—peripheral nervous system neoplasm	3.17e-05	0.00012	CcSEcCtD
Sildenafil—PDE5A—Hemostasis—HRAS—peripheral nervous system neoplasm	3.12e-05	0.00105	CbGpPWpGaD
Sildenafil—Dizziness—Doxorubicin—peripheral nervous system neoplasm	3.1e-05	0.000118	CcSEcCtD
Sildenafil—CYP2D6—Metabolism—PPIP5K2—peripheral nervous system neoplasm	3.09e-05	0.00104	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—PPIP5K2—peripheral nervous system neoplasm	3.07e-05	0.00103	CbGpPWpGaD
Sildenafil—Nausea—Epirubicin—peripheral nervous system neoplasm	3.01e-05	0.000114	CcSEcCtD
Sildenafil—ADORA2A—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	2.99e-05	0.00101	CbGpPWpGaD
Sildenafil—ABCC5—Metabolism—BCHE—peripheral nervous system neoplasm	2.99e-05	0.00101	CbGpPWpGaD
Sildenafil—Vomiting—Doxorubicin—peripheral nervous system neoplasm	2.98e-05	0.000113	CcSEcCtD
Sildenafil—Rash—Doxorubicin—peripheral nervous system neoplasm	2.95e-05	0.000112	CcSEcCtD
Sildenafil—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	2.95e-05	0.000112	CcSEcCtD
Sildenafil—ADORA2A—Signaling by NGF—NRAS—peripheral nervous system neoplasm	2.95e-05	0.000994	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.94e-05	0.000993	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—GNS—peripheral nervous system neoplasm	2.94e-05	0.000992	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.94e-05	0.000991	CbGpPWpGaD
Sildenafil—Headache—Doxorubicin—peripheral nervous system neoplasm	2.94e-05	0.000111	CcSEcCtD
Sildenafil—ADORA2A—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	2.93e-05	0.000989	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—VIP—peripheral nervous system neoplasm	2.92e-05	0.000986	CbGpPWpGaD
Sildenafil—ABCC5—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.85e-05	0.000961	CbGpPWpGaD
Sildenafil—ADORA2A—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	2.82e-05	0.000953	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—NME1—peripheral nervous system neoplasm	2.82e-05	0.000951	CbGpPWpGaD
Sildenafil—ABCC5—Metabolism—TH—peripheral nervous system neoplasm	2.81e-05	0.000947	CbGpPWpGaD
Sildenafil—ADORA2A—NGF signalling via TRKA from the plasma membrane—HRAS—peripheral nervous system neoplasm	2.8e-05	0.000946	CbGpPWpGaD
Sildenafil—PDE6G—Disease—ERBB2—peripheral nervous system neoplasm	2.78e-05	0.000939	CbGpPWpGaD
Sildenafil—Nausea—Doxorubicin—peripheral nervous system neoplasm	2.78e-05	0.000106	CcSEcCtD
Sildenafil—CYP1A1—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.78e-05	0.000937	CbGpPWpGaD
Sildenafil—PDE5A—Hemostasis—AKT1—peripheral nervous system neoplasm	2.75e-05	0.000929	CbGpPWpGaD
Sildenafil—ABCC4—Hemostasis—PTPN11—peripheral nervous system neoplasm	2.72e-05	0.000919	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—COX2—peripheral nervous system neoplasm	2.71e-05	0.000915	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	2.7e-05	0.00091	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	2.56e-05	0.000865	CbGpPWpGaD
Sildenafil—ADORA2A—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	2.48e-05	0.000835	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.47e-05	0.000832	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	2.31e-05	0.000778	CbGpPWpGaD
Sildenafil—ABCC5—Metabolism—GNAS—peripheral nervous system neoplasm	2.29e-05	0.000773	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.27e-05	0.000766	CbGpPWpGaD
Sildenafil—ABCC5—Metabolism—ABCB1—peripheral nervous system neoplasm	2.25e-05	0.000759	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by NGF—HRAS—peripheral nervous system neoplasm	2.16e-05	0.000727	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—GNS—peripheral nervous system neoplasm	2.13e-05	0.000718	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—GNS—peripheral nervous system neoplasm	2.12e-05	0.000717	CbGpPWpGaD
Sildenafil—PDE6G—Disease—NRAS—peripheral nervous system neoplasm	2.12e-05	0.000714	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.09e-05	0.000705	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.07e-05	0.000699	CbGpPWpGaD
Sildenafil—ABCC4—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	2.05e-05	0.000692	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—NME1—peripheral nervous system neoplasm	2.04e-05	0.000689	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—NME1—peripheral nervous system neoplasm	2.04e-05	0.000687	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	2.03e-05	0.000683	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.02e-05	0.000682	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—GNS—peripheral nervous system neoplasm	2.01e-05	0.000677	CbGpPWpGaD
Sildenafil—PDE6G—Disease—MYC—peripheral nervous system neoplasm	1.97e-05	0.000666	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—COX2—peripheral nervous system neoplasm	1.96e-05	0.000663	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—COX2—peripheral nervous system neoplasm	1.96e-05	0.000661	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.95e-05	0.000658	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—NME1—peripheral nervous system neoplasm	1.92e-05	0.000649	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by NGF—AKT1—peripheral nervous system neoplasm	1.9e-05	0.000642	CbGpPWpGaD
Sildenafil—ABCC5—Disease—PTPN11—peripheral nervous system neoplasm	1.9e-05	0.000642	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	1.89e-05	0.000637	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—COX2—peripheral nervous system neoplasm	1.85e-05	0.000625	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.78e-05	0.000601	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—ENO2—peripheral nervous system neoplasm	1.78e-05	0.000601	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.77e-05	0.000597	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.73e-05	0.000585	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	1.72e-05	0.000581	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.65e-05	0.000557	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—GNS—peripheral nervous system neoplasm	1.64e-05	0.000554	CbGpPWpGaD
Sildenafil—ABCC4—Hemostasis—NRAS—peripheral nervous system neoplasm	1.64e-05	0.000552	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—NME1—peripheral nervous system neoplasm	1.57e-05	0.000531	CbGpPWpGaD
Sildenafil—PDE6G—Disease—HRAS—peripheral nervous system neoplasm	1.55e-05	0.000523	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—COX2—peripheral nervous system neoplasm	1.52e-05	0.000511	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.52e-05	0.000511	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—GNS—peripheral nervous system neoplasm	1.51e-05	0.00051	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—BCHE—peripheral nervous system neoplasm	1.5e-05	0.000508	CbGpPWpGaD
Sildenafil—ABCC5—Disease—ERBB2—peripheral nervous system neoplasm	1.5e-05	0.000507	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—GNS—peripheral nervous system neoplasm	1.5e-05	0.000505	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.48e-05	0.0005	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—NME1—peripheral nervous system neoplasm	1.45e-05	0.000489	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—NME1—peripheral nervous system neoplasm	1.44e-05	0.000484	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.44e-05	0.000484	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—TH—peripheral nervous system neoplasm	1.41e-05	0.000477	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—COX2—peripheral nervous system neoplasm	1.39e-05	0.00047	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—COX2—peripheral nervous system neoplasm	1.38e-05	0.000466	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.38e-05	0.000466	CbGpPWpGaD
Sildenafil—PDE6G—Disease—AKT1—peripheral nervous system neoplasm	1.37e-05	0.000462	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.37e-05	0.000461	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—ENO2—peripheral nervous system neoplasm	1.29e-05	0.000435	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—ENO2—peripheral nervous system neoplasm	1.29e-05	0.000434	CbGpPWpGaD
Sildenafil—ABCC4—Hemostasis—TP53—peripheral nervous system neoplasm	1.25e-05	0.000423	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—ENO2—peripheral nervous system neoplasm	1.22e-05	0.00041	CbGpPWpGaD
Sildenafil—ABCC4—Hemostasis—HRAS—peripheral nervous system neoplasm	1.2e-05	0.000404	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—GNAS—peripheral nervous system neoplasm	1.15e-05	0.00039	CbGpPWpGaD
Sildenafil—ABCC5—Disease—NRAS—peripheral nervous system neoplasm	1.14e-05	0.000386	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.13e-05	0.000383	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—ABCB1—peripheral nervous system neoplasm	1.13e-05	0.000382	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—BCHE—peripheral nervous system neoplasm	1.09e-05	0.000368	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—BCHE—peripheral nervous system neoplasm	1.09e-05	0.000367	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.09e-05	0.000366	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.07e-05	0.000362	CbGpPWpGaD
Sildenafil—ABCC5—Disease—MYC—peripheral nervous system neoplasm	1.07e-05	0.000359	CbGpPWpGaD
Sildenafil—ABCC4—Hemostasis—AKT1—peripheral nervous system neoplasm	1.06e-05	0.000357	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.05e-05	0.000355	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.04e-05	0.000351	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.04e-05	0.00035	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—BCHE—peripheral nervous system neoplasm	1.03e-05	0.000347	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—TH—peripheral nervous system neoplasm	1.02e-05	0.000346	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—TH—peripheral nervous system neoplasm	1.02e-05	0.000345	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—ENO2—peripheral nervous system neoplasm	9.95e-06	0.000336	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	9.88e-06	0.000333	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—SLC2A1—peripheral nervous system neoplasm	9.8e-06	0.000331	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—TH—peripheral nervous system neoplasm	9.66e-06	0.000326	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—AKT1—peripheral nervous system neoplasm	9.58e-06	0.000323	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	9.47e-06	0.000319	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	9.15e-06	0.000309	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	9.12e-06	0.000308	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—ENO2—peripheral nervous system neoplasm	9.07e-06	0.000306	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—BCHE—peripheral nervous system neoplasm	8.41e-06	0.000284	CbGpPWpGaD
Sildenafil—ABCC5—Disease—HRAS—peripheral nervous system neoplasm	8.37e-06	0.000282	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—GNAS—peripheral nervous system neoplasm	8.37e-06	0.000282	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—GNAS—peripheral nervous system neoplasm	8.35e-06	0.000282	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	8.32e-06	0.000281	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—ABCB1—peripheral nervous system neoplasm	8.21e-06	0.000277	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—ABCB1—peripheral nervous system neoplasm	8.19e-06	0.000276	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—SLC2A1—peripheral nervous system neoplasm	8.02e-06	0.000271	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—TH—peripheral nervous system neoplasm	7.91e-06	0.000267	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—GNAS—peripheral nervous system neoplasm	7.89e-06	0.000266	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	7.84e-06	0.000264	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—ABCB1—peripheral nervous system neoplasm	7.74e-06	0.000261	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	7.73e-06	0.000261	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—BCHE—peripheral nervous system neoplasm	7.67e-06	0.000259	CbGpPWpGaD
Sildenafil—ADORA2A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	7.62e-06	0.000257	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	7.55e-06	0.000255	CbGpPWpGaD
Sildenafil—ABCC5—Disease—AKT1—peripheral nervous system neoplasm	7.39e-06	0.000249	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	7.38e-06	0.000249	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—SLC2A1—peripheral nervous system neoplasm	7.31e-06	0.000247	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	7.27e-06	0.000245	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—TH—peripheral nervous system neoplasm	7.21e-06	0.000243	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	6.92e-06	0.000234	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—GNAS—peripheral nervous system neoplasm	6.45e-06	0.000218	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—ABCB1—peripheral nervous system neoplasm	6.33e-06	0.000214	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	6.33e-06	0.000214	CbGpPWpGaD
Sildenafil—ABCC5—Metabolism—AKT1—peripheral nervous system neoplasm	6.19e-06	0.000209	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	5.98e-06	0.000202	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	5.94e-06	0.0002	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.9e-06	0.000199	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—GNAS—peripheral nervous system neoplasm	5.89e-06	0.000199	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	5.83e-06	0.000197	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—ABCB1—peripheral nervous system neoplasm	5.77e-06	0.000195	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	5.06e-06	0.000171	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.84e-06	0.000163	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	4.82e-06	0.000163	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	4.75e-06	0.00016	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.63e-06	0.000156	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.09e-06	0.000138	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	3.88e-06	0.000131	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	3.81e-06	0.000128	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—AKT1—peripheral nervous system neoplasm	3.12e-06	0.000105	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—AKT1—peripheral nervous system neoplasm	2.26e-06	7.62e-05	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—AKT1—peripheral nervous system neoplasm	2.25e-06	7.6e-05	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—AKT1—peripheral nervous system neoplasm	2.13e-06	7.18e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—AKT1—peripheral nervous system neoplasm	1.74e-06	5.88e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	1.6e-06	5.41e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—AKT1—peripheral nervous system neoplasm	1.59e-06	5.36e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	1.05e-06	3.53e-05	CbGpPWpGaD
